185 related articles for article (PubMed ID: 24205991)
1. γ-Cyclodextrin nanoparticle eye drops with dorzolamide: effect on intraocular pressure in man.
Gudmundsdottir BS; Petursdottir D; Asgrimsdottir GM; Gottfredsdottir MS; Hardarson SH; Jóhannesson G; Kurkov SV; Jansook P; Loftsson T; Stefánsson E
J Ocul Pharmacol Ther; 2014 Feb; 30(1):35-41. PubMed ID: 24205991
[TBL] [Abstract][Full Text] [Related]
2. Dorzolamide cyclodextrin nanoparticle suspension eye drops and Trusopt in rabbit.
Jóhannesson G; Moya-Ortega MD; Asgrímsdóttir GM; Agnarsson BA; Lund SH; Loftsson T; Stefánsson E
J Ocul Pharmacol Ther; 2014 Aug; 30(6):464-7. PubMed ID: 24734973
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic equivalence study of two preparations of eye drops containing dorzolamide and timolol in healthy volunteers.
Gatchev E; Petrov A; Kolev E; Hristova R; Demircheva I; Koytchev R; Richter W; Tegel F; Thyroff-Friesinger U
Arzneimittelforschung; 2011; 61(5):282-6. PubMed ID: 21755811
[TBL] [Abstract][Full Text] [Related]
4. Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension.
Gudmundsdóttir E; Stefánsson E; Bjarnadóttir G; Sigurjónsdóttir JF; Gudmundsdóttir G; Masson M; Loftsson T
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3552-4. PubMed ID: 11006251
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid.
Jóhannesson G; Moya-Ortega MD; Ásgrímsdóttir GM; Lund SH; Thorsteinsdóttir M; Loftsson T; Stefánsson E
Acta Ophthalmol; 2014 Sep; 92(6):550-6. PubMed ID: 24373641
[TBL] [Abstract][Full Text] [Related]
6. Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles.
Park CG; Kim YK; Kim SN; Lee SH; Huh BK; Park MA; Won H; Park KH; Choy YB
Int J Pharm; 2017 Apr; 522(1-2):66-73. PubMed ID: 28216468
[TBL] [Abstract][Full Text] [Related]
7. [Postoperative behavior of intraocular pressure after posterior Nd:YAG laser capsulotomy--critical evaluation in preventive administration of local carbonic anhydrase II inhibitor dorzolamide hydrochloride (Trusopt)].
Lachmann C; Jörg KM; Trinkmann R
Klin Monbl Augenheilkd; 1998 Dec; 213(6):326-30. PubMed ID: 10048009
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide.
Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):17-24. PubMed ID: 10598693
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of intraocular-pressure- lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide.
Seong GJ; Lee SC; Lee JH; Chu YK; Hong YJ
Ophthalmologica; 2001; 215(3):188-91. PubMed ID: 11340389
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components.
Strohmaier K; Snyder E; DuBiner H; Adamsons I
Ophthalmology; 1999 Dec; 106(12 Suppl):1-9. PubMed ID: 10598691
[TBL] [Abstract][Full Text] [Related]
11. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol -- a randomized controlled trial and a replacement study.
Francis BA; Du LT; Berke S; Ehrenhaus M; Minckler DS;
J Clin Pharm Ther; 2004 Aug; 29(4):375-80. PubMed ID: 15271105
[TBL] [Abstract][Full Text] [Related]
12. Changes in intraocular pressure associated with topical dorzolamide and oral methazolamide in glaucomatous dogs.
Gelatt KN; MacKay EO
Vet Ophthalmol; 2001 Mar; 4(1):61-7. PubMed ID: 11397321
[TBL] [Abstract][Full Text] [Related]
13. [The hypotensive action and side effects of the carboanhydrase inhibitor dorzolamide hydrochloride].
Egorov AE
Vestn Oftalmol; 1996; 112(2):3-4. PubMed ID: 9045485
[TBL] [Abstract][Full Text] [Related]
14. Retrobulbar hemodynamics before and after oculopression with and without dorzolamide.
Huber-van der Velden KK; Lux A; Severing K; Klamann MK; Winterhalter S; Remky A
Curr Eye Res; 2012 Aug; 37(8):719-25. PubMed ID: 22642452
[TBL] [Abstract][Full Text] [Related]
15. 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma.
Feldman RM; Stewart RH; Stewart WC; Jia G; Smugar SS; Galet VA
Curr Med Res Opin; 2008 Aug; 24(8):2403-12. PubMed ID: 18627642
[TBL] [Abstract][Full Text] [Related]
16. Topical drug delivery to the eye: dorzolamide.
Loftsson T; Jansook P; Stefánsson E
Acta Ophthalmol; 2012 Nov; 90(7):603-8. PubMed ID: 22269010
[TBL] [Abstract][Full Text] [Related]
17. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
[TBL] [Abstract][Full Text] [Related]
18. Effects of ocular administration of ophthalmic 2% dorzolamide hydrochloride solution on aqueous humor flow rate and intraocular pressure in clinically normal cats.
Rankin AJ; Crumley WR; Allbaugh RA
Am J Vet Res; 2012 Jul; 73(7):1074-8. PubMed ID: 22738060
[TBL] [Abstract][Full Text] [Related]
19. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
20. [Ocular hemodynamics and visual field in glaucoma treated with dorzolamide].
Bernd AS; Pillunat LE; Böhm AG; Schmidt KG; Richard G
Ophthalmologe; 2001 May; 98(5):451-5. PubMed ID: 11402826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
